Product Code: RP-ID-10151806 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151806
Market Overview:
Global T-cell Acute Lymphoblastic Leukemia Treatment Industry Market Research 2022-2030
"The global T cell acute lymphoblastic leukemia treatment market is estimated to be valued at USD 3 billion in 2021 and is projected to grow at ~12% over the period 2022-2030. The rising incidence of acute lymphoblastic leukemia (ALL) and increasing initiatives by public and private organizations are one of the major drivers of market growth, and advances in infectious cell detection technologies are the driving force behind the market growth. .. DEVELOPMENT For example, treatment of chimeric antigen receptor (CAR) T cells with Novartis AG is a novel therapy. The treatment is in phase 2 clinical trials and is expected to be approved by the FDA in 2020.
Several government and non-governmental organizations such as the National Cancer Institute, National Cancer Institute (NCI) and National Institutes of Health have launched Just-in-case screening initiatives and campaigns. St. There are several programs in TARGET and targeted cancer treatment workshops for the detection of children's cancer in several countries, including Jude Children Research Hospital, University of New Brunswick and Mexico, and we have collaborated with several research groups. done. And it can better process the patient's blood. According to the American Cancer Society, in 2017, an estimated 2,620 women and 3,350 men will all be diagnosed with the disease, and 640 women and 800 men are expected to die from the disease.
Types of discovery:
ALL is divided into three types: Philadelphia chromosomes (Ph), B-ALL precursors and ALL-ALL-T cells. The Philadelphia chromosome (Ph) is also classified as PHALL positive and PHALL negative. The risk of developing the disease increases with age, and the most common drugs used to treat ALL are tyrosine kinase inhibitors, such as dasatinib (Sprycel), imatinib (Gleevec), and nilotinib (Tasigna). The above drugs show one of the symptoms of acute lymphoblastic leukemia. Drugs used to treat chronic myeloid leukemia usually also have the potential to treat acute lymphoblastic leukemia. The former B-ALL dominated the market in 2016 thanks to its rapid growth and high contamination rate in the early stages. With increasing prevalence of the disease among adults, the region is expected to experience the fastest growth during the forecast period. According to the National Comprehensive Cancer Network (NCCN), a subset of B cells begins with young cells formed in the bone marrow and eventually develops into adult B cells (B lymphomas) with Burkitt-type ALL (reaching B). ). lead diseases are all). This is the most common subgroup of LAL. All B cell progenitors are BCR-ABL genes and divide into adult B cells (Burkitt type). A. 4% of the total.
Regional Outlook:
North America dominated the market in 2020. They make up most of the major U.S. manufacturers and have built up healthcare infrastructure. Significant growth is also expected with the launch of Besponsa (non-invasive Zhumabu ozogamicin) in the US in August 2017 and the launch of potent drugs such as Response in phase 2 clinical trials. The Pacific region is expected to grow.
Faster competitiveness with non-clinical needs, high disposable income, availability of effective treatments, and a lucrative CAGR of 11% during the forecast period in emerging markets such as China and India. .. Spectrum Pharmaceuticals, Inc. Pfizer Corporation Sigma-Tau Sp. And Genzyme Co., Ltd. Manufacturers conduct in-depth clinical trials and explore untapped opportunities as these major players pursue strategies such as mergers and acquisitions to develop new products for existing drugs. , trying to identify a new indicator. For example, in June 2015, Celgene announced a partnership with Juno Therapeutics to develop and commercialize a unique immunosuppressive therapy for autoimmune diseases and cancer.
Sections Reported in This Report:
This report forecasts the revenue growth for each of the following industries from 2022-2030 and provides analysis of industry trends For this study, Kenneth Research has segmented the acute lymphoblastic leukemia treatment market by type and treatment. Other Regions: Treatment Prospects (Revenue, USD 1M, 2022-2030 ) Hyper-CVAD CALGB Chemotherapy 8811 Linker Nucleoside Metabolism Inhibitor (Linked to OnCaspar Targeted Stem Cell Radiation Therapy) Type of Forecast (Release, USD Million Chromium) , 2051) whole Philadelphia cells"
Related Reports
Proof of Quality & Reliability
